Clinical Pharmacy and Clinical Pharmacology

William A. Gouveia Gianni Tognoni Eppo van der Kleijn (editors)



NORTH-HOLLAND

Clinical Pharmacy and Clinical Pharmacology

Proceedings of an International Symposium held in Boston, Mass., USA – September 17–19 1975



William A. Gouveia Gianni Tognoni Eppo van der Kleijn

1976



© Elsevier/North-Holland Biomedical Press 1976

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner.

Library of Congress Cataloging in Publication Data

Main entry under title:

Clinical pharmacy and clinical pharmacology.
Bibliography: p.
Includes index.

1. Pharmacology–Congresses. 2. Pharmacy–Congresses. 3. Pediatric pharmacology–Congresses. 4. Information storage and retrieval systems–Medicine–Congresses. I. Gouveia, William A. II. Tognoni, Gianni. III. Kleijn, Eppo van der. [DNLM: 1. Drug therapy–Congresses. 2. Pharmacy–Congresses. 3. Pharmacology–Congresses. WB330 C638 1975]
RM300.C56 615′.1 76-40890
ISBN 0-7204-0596-3

(xIV + 464 pages, 146 Figures, 86 Tables)

PUBLISHERS Elsevier/North-Holland Biomedical Press 335 Jan van Galenstraat, P.O. Box 211 Amsterdam, The Netherlands

SOLE DISTRIBUTORS FOR THE U.S.A. AND CANADA Elsevier/North-Holland, Inc. 52 Vanderbilt Avenue
New York, N.Y. 10017, U.S.A.

Printed in The Netherlands

This conference gives some examples of how many initiatives could be undertaken towards improving therapy. While new medical diagnostic procedures have been developed, relatively little has been done to cope with therapeutic needs, the dominant concept being that when the diagnosis is made the therapy is an automatic consequence. Yet, the development of powerful drugs which often produce marked side-effects and the multiplicity of possible treatments for the same symptoms make it imperative that therapy becomes a critical and specialized medical activity. The message from this meeting is that the therapeutic activity should be supported by adequate structures such as now exist in the hospitals for the diagnostic process. The recommendation is, therefore, that departments of therapeutics (the name is not essential) be created.

It is possible to envision at least four main functions for these departments.

- 1. Drug information. Few practitioners can keep up with the enormous amount of literature reporting new findings about the action and the clinical use of old and new drugs. This information may require very sophisticated approaches in the future, including the use of computers.
- 2. Laboratory work. It is becoming increasingly evident that measuring plasma levels of drugs may be of help for an individualized therapy. There are diseases, such as epilepsy and depression, which show a higher percentage of cures if monitoring of drug plasma is coupled with pharmacokinetic competence. In addition, biochemical tests may be of importance for certain types of therapy in predicting the results, e.g. the determination of estrogen receptors for the therapy of breast cancer.
- 3. Monitoring of side-effects. While it may be relatively easy to recognize common undesired effects of drugs, it requires a complex organization to determine rare and sometimes unexpected or latent effects of drugs. In this respect, the department of therapeutics can perform an important task as part of national or international programs aimed at detecting comparative data on toxic effects of drugs.
- 4. Therapeutic trials. There is a tremendous need to evaluate drugs, doses, and therapeutic protocols, in well-controlled conditions. Some of these trials can be performed inside the same hospital, but many require collaboration with other organizations. Hence, there is a need to have available scientists with competence in this particular area.

V

The establishment of departments of therapeutics does not necessarily require completely new structures, because frequently it may be enough to pool a competent staff already existing in a given hospital. It is important, however, that there be available at the service of the physician engaged in the difficult task of therapeutic delivery, pharmacologists, pharmacists, biochemists, and statisticians, in the effort to bring to the patient the best of the new scientific knowledge.

Silvio Garattini Milan, March 1976

Symposium Organizing Committee

William A. Gouveia, MS, Boston, Mass., U.S.A. Gianni Tognoni, MD, Milan, Italy Silvio Garattini, MD, Milan, Italy David J. Greenblatt, MD, Boston, Mass., U.S.A. Eppo van der Kleijn, PhD, Nijmegen, The Netherlands Russell R. Miller, PharmD, PhD, Boston, Mass., U.S.A. William A. Miller, PharmD, Memphis, Tenn., U.S.A.

Acknowledgements

A large number of individuals must combine their efforts in the arrangement of a meeting and the subsequent publication of proceedings of that meeting. Among those who made outstanding contributions to this work are:

Monica F. Loeb and R. Lynn Shumake of New England Medical Center Hospital. Dr. Norman S. Stearns and Emelie Born of Tufts University School of Medicine. Drs. Raymond A. Gosselin and Benjamin Hershenson of Massachusetts College of Pharmacy.

The financial support of the following companies is gratefully acknowledged.

Beecham Pharmaceutical Company
Burroughs Wellcome Company
Ciba-Geigy Corporation
Dow Pharmaceutical Company
Merck, Sharp and Dohme Company
Organon International
Roche Laboratories
SAGO, S.p.A., Florence, Italy
Searle Laboratories
Smith, Kline and French Laboratories
Warner-Chilcott Laboratories

List of Contributors

Michael Barza, MD

Assistant Professor (Medicine) Assistant Attending Physician

New England Medical Center Hospital

BOSTON, Mass., USA

A.J.M.M. Beysens

Department of Pharmacy

Maria Hospital

TILBURG, The Netherlands

Alasdair Muir Breckenridge

Professor of Clinical Pharmacology Department of Pharmacology

The University

LIVERPOOL, England

Douwe D. Breimer, PhD

Professor of Pharmacology Subfaculty of Pharmacy University of Leiden LEIDEN, The Netherlands

Candace K. Bryan, PharmD

School of Pharmacy

University of North Carolina CHAPEL HILL, N. Car., USA

Lloyd J. Christopher, MD

Aberdeen-Dundee Medicines Evaluation and

Monitoring Group Ninewells Hospital Aberdeen Royal Infirmary ABERDEEN, Scotland

Henry Derewicz

Director

Department of Pharmacy Services The Johns Hopkins Hospital BALTIMORE, Md., USA

Luzius Dettli, MD

Professor of Medicine

University of Basel Kantonsspital

BASEL, Switzerland

Alberto DiMascio, MD

Boston State Hospital BOSTON, Mass., USA Silvio Garattini, MD

Director

Istituto di Ricerche Farmacologiche

Mario Negri MILAN, Italy

Sydney S. Gellis, MD

Pediatrician-in-Chief

New England Medical Center Hospital

Professor of Pediatrics

Tufts University School of Medicine

BOSTON, Mass., USA

William A. Gouveia, MS

Director of Pharmacy

New England Medical Center Hospital Associate Clinical Professor of Pharmacy Massachusetts College of Pharmacy

Assistant Clinical Professor of Oral Surgery Tufts University School of Dental Medicine

BOSTON, Mass., USA

David J. Greenblatt, MD

Acting Chief

Clinical Pharmacology Unit Massachusetts General Hospital Assistant Professor of Medicine Harvard Medical School BOSTON, Mass., USA

Margaretha Helling

Scientist. Pharmaceuticals

Division of Prophylactic, Diagnostic and Therapeutic

Substances

World Health Organization GENEVA, Switzerland

Adriaan J. Hoelen

Sint Radboud Ziekenhuis Katholieke Universiteit NIJMEGEN, The Netherlands

Dallas J. Howe

Associate Director

Hospital Systems Study Group

SASKATOON, Saskatchewan, Canada

J. Heyward Hull*, MS

Assistant Professor

Divisions of Pharmaceutics and Pharmacy Practice

University of North Carolina

Clinical Pharmacist

North Carolina Memorial Hospital CHAPEL HILL, N. Car., USA

Duncan E. Hutcheon, MD, DPhil

Departments of Pharmacology and Medicine College of Medicine and Dentistry of New Jersey

NEWARK, N.J., USA

Hershel Jick, MD

Associate Professor of Medicine Boston University School of Medicine

WALTHAM, Mass., USA

Stanley A. Kaplan, PhD

Associate Director

Department of Biochemistry and Drug Metabolism

Hoffman-La Roche, Inc. NUTLEY, NJ., USA

Kim L. Kelly, PharmD

Docent Clinical Pharmacist

Associate Professor

University of Missouri at Kansas City Schools of

Pharmacy and Medicine KANSAS CITY, Mo., USA

Jan Koch-Weser, MD

Director of Medical Research

Centre de Recherche Merrell Internationale

STRASBOURG, France

Robert F. Maronde, MD

Professor of Medicine and Clinical Pharmacology

Head

Section of Clinical Pharmacology

University of Southern California School of Medicine

LOS ANGELES, Calif., USA

Thomas J. Mattei, PharmD

Associate Director

Pharmacy Services and Education Mercy Hospital of Pittsburgh Assistant Professor and Chairman Department of Clinical Pharmacy

Duquesne University PITTSBURGH, Pa., USA

Russell R. Miller, PharmD, PhD

Director, Division of Clinical Pharmacy New England Medical Center Hospital

Senior Investigator

Boston Collaborative Drug Surveillance Program

Boston University Medical Center

BOSTON, Mass., USA

William A. Miller, MSc, PharmD

Chairman

Department of Pharmacy Practice

University of Tennessee Center for the Health Sciences

Director of Pharmacy City of Memphis Hospitals MEMPHIS, Tenn., USA

Allen A. Mitchell, MD

Assistant in Medicine and Clinical Pharmacology

Children's Hospital Medical Center

Instructor in Pediatrics Harvard Medical School Senior Investigator Drug Epidemiology Unit Boston University Medical Center

BOSTON, Mass., USA

P.L. Morselli, MD

Istituto di Ricerche Farmacologiche

Mario Negri MILAN, Italy

Craig B. Nielsen, BS Pharm

Coordinator

Computerized Pharmacy Services Department of Pharmacy Ohio State University Hospitals COLUMBUS, Ohio, USA

Anders Rane, MD

Department of Clinical Pharmacology

Karolinska Institute

Huddinge University Hospital

HUDDINGE/STOCKHOLM, Sweden

Richard N. Re, MD

Assistant in Medicine

Massachusetts General Hospital

Instructor in Medicine Harvard Medical School BOSTON, Mass., USA

D.S. Reeves, MD

Consultant Medical Microbiologist

Southmead Hospital Clinical Teacher University of Bristol BRISTOL, England

Marcus M. Reidenberg, MD

Professor of Pharmacology Associate Professor of Medicine Cornell University Medical College NEW YORK, N.Y., USA

Richard I. Shader, MD

Department of Psychiatry Harvard Medical School

Massachusetts Mental Health Center

BOSTON, Mass., USA

Edward H. Shortliffe, MD, PhD

Resident in Medicine

Massachusetts General Hospital

BOSTON, Mass., USA

Gianni Tognoni, MD

Head

Laboratory of Clinical Pharmacology Istituto di Ricerche Farmacologiche

Mario Negri MILAN, Italy

Carl E. Trinca, MS

Clinical Instructor College of Pharmacy

Instructor of Clinical Pharmacology

College of Medicine University of Arizona TUCSON, Ariz., USA E. van der Kleijn, PhD Head

Clinical Pharmacy, Department Sint Radboud Hospital

NIJMEGEN, The Netherlands

Tom B. Vree, PhD Department of Clinical Pharmacy

Sint Radboud Hospital University of Nijmegen

NIJMEGEN, The Netherlands

Charles A. Walton, PhD Professor and Assistant Dean

College of Pharmacy

The University of Texas at Austin Professor of Pharmacology

The University of Texas Health Science Center at San Antonio

SAN ANTONIO, Tex., USA

Miles Weinberger, MD Department of Pediatrics

University of Iowa IOWA CITY, Iowa, USA

Barbro Westerholm, MD Associate Professor

Medical Advisor

National Corporation of Swedish Pharmacies

STOCHOLM, Sweden

Sumner J. Yaffe, MD Professor of Pediatrics and Pharmacology

The University of Pennsylvania

Director

Division of Clinical Pharmacology
The Children's Hospital of Philadelphia

PHILADELPHIA, Pa., USA

Contents

PREFACE ACKNOWLEDGEMENTS LIST OF CONTRIBUTORS	V VII IX
Seminar I: Clinical Psychopharmacology A. DiMascio (mod E. van der Kleijn (s	
Chapter 1: Psychopharmacokinetics D.J. Greenblatt & R.I. Shader	3
hypnotic drug therapy D.D. Breimer	17
E. van der Kleijn, P.J.M. Guelen, I.M. Baars, T.B. Vree & E. Termond	43
M. Hoes & J.S.F. Grimbère	67
Seminar II: Antihypertensive Therapy A. Breckenridge (mode D.J. Greenblatt (e)	
Moderator's comment	91
Chapter 5: Modern approaches to the treatment of hypertension J. Koch-Weser	93
Chapter 6: Beta-blockers in hypertension: a review	105
K.L. Kelly	105
R. Re	119
T.J. Mattei	125

Seminar II	I: Adverse Drug Reactions	J. Koch-Weser (moder: R.R. Miller (ed	
	Moderator's comment		135
Chapter 9:	Experience with World Health Organization		
63 (124) 144	M. Helling		141
Chapter 10:	Sources of information on adverse reactions and drug consumption		
	B. Westerholm		153
Chapter 11:	Experience with the Aberdeen–Dundee Drug		
	Monitoring System	7 C Fuelsing	165
Chantan 12.	L.J. Christopher, C.R. Henney, D.C. Moir & . Experiences of the Boston Collaborative	Z.G. Erskine	103
Chapter 12:			
	Drug Surveillance Program		179
Chapter 12.	H. Jick		1/9
Chapter 13.	pharmacologist: the logical drug surveillance	team	
	C.F. T.	team	183
	C.E. Trinca	erimiewidzekt i sky	103
Seminar I	V: Antimicrobial Therapy	.S. Reeves (moderator & ed	ditor)
Chapter 14:	Clinical pharmacokinetics of co-trimoxazole		
	S.A. Kaplan & C.W. Abruzzo		193
Chapter 15:	Predictability of blood levels of gentamicin in		
	M. Barza, R.B. Brown, D. Shen, M. Gibaldi		207
Chapter 16:	Pharmacological studies with carfecillin and		
	talampicillin, two esters of broad spectrum pe	enicillins	
	D.S. Reeves, M.J. Bywater, H.A. Holt & P.J.		223
Chapter 17:	Prediction of drug elimination in patients wit		
	renal disease based on kinetic parameters		
	determined in small samples of patients with		
	normal or impaired kidney function		
	L. Dettli & C. Tschanz		235
Chapter 18:	Clinical assessment of pharmacokinetic parar	neters	
	in the surveillance and design of gentamicin t		
	J.H. Hull & F.A. Sarubbi Jr	. [4] [1] [1] [1] [1] [1] [1] [1] [1] [1] [1	247
Chapter 19:	A computer-based approach to the promotion	n of	
	rational clinical use of antimicrobials		
	E.H Shortliffe, S.G. Axline, B.G. Buchanan,		
	R. Davis & S.N. Cohen		259

Seminar V: Pediatric Pharmacology	C T '(1'4)
Chapter 20: Pediatric clinical pharmacology: routine	
monitoring or clinical trials?	
P.L. Morselli	
Chapter 21: Digoxin disposition (tissue distribution and renal clearance) in infants	
S.J. Yaffe, R. Gorodischer & W.J. Jusko	289
Chapter 22: Plasma level monitoring of diphenylhydantoin	
and carbamazepine in the pediatric patient	
A. Rane & J.T. Wilson	295
Chapter 23: Perception of disease and compliance with	
pediatric medical regimens and the effects on	
assessment of treatment in ambulatory disease	
C.K. Bryan & J.H. Bryan	
Chapter 24: Intensive drug surveillance in a pediatric hospital	
A.A. Mitchell, P. Goldman, S. Shapiro,	
V. Siskind & D. Slone	
Chapter 25: Theophyllinization of the child with chronic asthm	
M. Weinberger & E. Ginchansky	
The monte of the Distriction of	
Seminar VI: Information Systems W.A. Goun	veia (moderator & editor)
Moderator's comment	331
Chapter 26: A large computer system to support unit dose distr in satellite pharmacies	
H.J. Derewicz	333
Chapter 27: A large-scale information system for a centralized J	pharmacy
C.B. Nielsen	339
Chapter 28: A collaborative effort to develop a	
computerized pharmacy system	
D.J. Howe	353
Chapter 29: Interaction of a computer-assisted drug	
information system with a community hospital pra	ctice
G. Tognoni, G. Beltrami, F. Colombo, A. Niccoli,	and the same of th
M. Pedrazzi, E. Villa & A. Andreani	375
Chapter 30: Registering incompatibilities and interactions	
by the computer	
A.J. Beysens	391

Chapter 31:	Data collection and analysis of drug usage	
	in an outpatient pharmacy	
	R.F. Maronde, D.C. Brodie & J.M. Leedom	. 399
Chapter 32:	The introduction of EDP systems for drug management	
	A.J. Hoelen & E. van der Kleijn	. 405
Seminar V	/II: Roles, Tasks and Functions D.E. Hutcheon (moderator	& editor
	Moderator's comment	. 425
Chapter 33:	Views of a pharmacy educator	
	C.A. Walton	. 42
Chapter 34:	Views of a clinical pharmacist	
	W.A. Miller	. 435
Chapter 35:	: Views of an academician	
	M.M. Reidenberg	. 44:
Chapter 36:	: Views of an hybrid pharmacist–pharmacologist	
	R.R. Miller	. 449
SUBJECT I	NDEX	. 45:

Seminar I

Clinical Psychopharmacology

A. DiMascio (moderator) E. van der Kleijn (editor)

Chapter 1:	Psychopharmacokinetes D.J. Greenblatt & R.I. Shader	
Chapter 2:	Pharmacokinetic and biopharmaceutical aspects of hypnotic drug therapy D.D. Breimer	17
Chapter 3:	Clinical pharmacokinetics of antiepileptic drugs E. van der Kleijn, P.J.M. Guelen, I.M. Baars, T.B. Vree & E. Termond	43
Chapter 4:	Clinical toxicology of central depressant and stimulant drugs T.B. Vree, E. van der Kleijn, A.G. van de Bogert,	6

试读结束,需要全本PDF请购买 www.ertongbook.com